Profectus BioSciences, Inc. Receives $5.4M Grant to Develop a Monocolonal Antibody Against Infection by Nipah/Hendra Viruses

Published: Dec 13, 2011

BALTIMORE--(BUSINESS WIRE)--Profectus BioSciences, Inc. (Profectus), a leader in the development of therapeutic and preventive vaccines against infectious diseases and cancers, announced today it has received a grant under the Partnerships for Biodefense RFA by the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH. This $5.4M award supports the preclinical development of m102.4, an antibody intended as a post-exposure prophylactic against Nipah or Hendra virus infection.

Back to news